PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Retatrutide Delivers 18.8% Weight Loss in Type 2 Diabetes at 80 Weeks

★ Editor's PickretatrutideGIP/GLP-1/glucagon receptor agonistobesitytype 2 diabetesweight managementphase 3 RCTTRIUMPH-2endocrinologyglycaemic controlsafety Endocrinology / Diabetes / Obesity

Background Information

In TRIUMPH-2, retatrutide 12 mg cut body weight 18.8% over 80 weeks in adults with type 2 diabetes, versus 5.1% on placebo.

Obesity and type 2 diabetes are closely linked, and effective treatments are needed to manage both conditions simultaneously. Retatrutide 12 mg reduced bodyweight by 18.8% compared to 5.1% with placebo. All doses improved glycemic control. Retatrutide shows promise for obesity and diabetes management, but gastrointestinal side effects and higher discontinuation rates may limit its use. Retatrutide significantly reduces bodyweight and improves glycemic control but requires monitoring for gastrointestinal side effects.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A

Citation: Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.